Skip to main content
Find more clinical trials

Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease, and Controls

Start: January 2010
End: July 2014
Enrollment: 99

What Is This Study About?

This study is designed to document the loss of social and moral emotions (such as empathy, guilt, and embarrassment) in patients with behavioral variant frontotemporal dementia (bvFTD). The loss of these emotions, which motivate social behavior, will become evident in specific interpersonal behaviors. These behaviors will correlate with regional changes in the medial frontal and anterior temporal lobes. These social and emotional changes will be compared with those in a young-onset Alzheimer's disease group.

Do I Qualify To Participate in This Study?

Minimum Age: 40 Years

Maximum Age: 75 Years

Must have:

Participants

++Core diagnostic features of bvFTD or NINCDS-ADRDA criteria for probable Alzheimer's disease++Mild-moderate cognitive and functional severity, defined as MMSE score of 10 or more and CDR of 2.0 or less++Ability to hear and understand instructions and respond to stimuli++English as primary language++Minimally impaired language++Medical stability (defined as absence of medical illness that would interfere with the ability to understand and participate in study procedures)++Caregiver to facilitate participation

Study Partners/Caregivers

++Visits and interaction with the subject at least once a week for 1 hour++Ability to accompany the subject to each visit++Ability to provide opinions about the subject's thinking, daily activities, and behavior++Willingness to share personal information, including feelings of distress about the subject's behavior or feelings of burden by caregiving responsibilities++Ability to read, understand, and speak English fluently

Must NOT have:

Participants

++Neurological or psychiatric illness other than bvFTD or probable Alzheimer's disease++Cortical infarction, other cortical lesion, or significant subcortical lesion on MRI of brain++Prohibited medications: potentially confounding medications, particularly those with effects on the peripheral nervous system, cardiovascular agents, and β-blockers

Controls

++Neurological or psychiatric illness++Currently a caregiver for a dementia patient (for at least 1 year)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Jill Shapira, RN, PhD
Michelle Mather, BA

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

California
UCLA Department of Neurology
Los Angeles, CA 90095
Recruiting
Michelle Mather, BA

Who Sponsors This Study?

Lead: University of California, Los Angeles

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT01147679